2. Signaling Pathways
  3. Neuronal Signaling
  4. Amyloid-β

Amyloid-β

β-amyloid peptide; Aβ; Abeta

Amyloid-β

Related Products

PDF 1.52 MB

Amyloid-β (Aβ) denotes peptides of 36–43 amino acids that are crucially involved in Alzheimer's disease as the main component of theamyloid plaques found in the brains of Alzheimer patients. The peptides result from the amyloid precursor protein (APP), which is being cut by certain enzymes to yield Aβ. Amyloid-β molecules can aggregate to form flexible soluble oligomers which may exist in several forms. Amyloid-β peptide is due to overproduction of Aβ and/or the failure of clearance mechanisms. Amyloid-β self-aggregates into oligomers, which can be of various sizes, and forms diffuse and neuritic plaques in the parenchyma and blood vessels. Amyloid-β oligomers and plaques are potent synaptotoxins, block proteasome function, inhibit mitochondrial activity, alter intracellular Ca2+levels and stimulate inflammatory processes. Loss of the normal physiological functions of Aβ is also thought to contribute to neuronal dysfunction.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P1850
    β-Amyloid (1-20)
    		99.67%
    β-Amyloid (1-20) consists of amino acids 1 to 20 of beta amyloid protein.
    β-Amyloid (1-20)
  • HY-P4886
    Amyloid β-Protein (3-42)
    		99.20%
    Amyloid β-Protein (3-42) is the precursor of Pyr peptide. Pyroglutamate-modified Aβ (pEAβ) (3-42) is the core of the amyloid template block in Alzheimer's disease. pEAβ(3-42) accelerated the aggregation of Aβ(1-42), while Aβ(1-42) significantly slowed the primary and secondary nucleation of pEAβ(3-42).
    Amyloid β-Protein (3-42)
  • HY-P5333A
    Aβ1-14-εK-KKK-MvF5 Th acetate
    		Inhibitor 99.93%
    Aβ1-14-εK-KKK-MvF5 Th acetate is the acetate salt form of Aβ1-14-εK-KKK-MvF5 Th (HY-P5333). Aβ1-14-εK-KKK-MvF5 Th acetate is part of UB-311 vaccine, that targets the amyloid-beta (Aβ) protein, and ameliorates the Alzheimer’s disease.
    Aβ1-14-εK-KKK-MvF5 Th acetate
  • HY-P0128F
    FITC-β-Amyloid (25-35)
    		98.80%
    FITC-β-Amyloid (25-35) is a FITC (HY-66019) labeled β-Amyloid (25-35) (HY-P0128)
    FITC-β-Amyloid (25-35)
  • HY-100275
    MK-3328
    		Inhibitor 99.70%
    MK-3328 is a β-Amyloid ligand, which exhibits high binding potency with an IC50 of 10.5 nM. MK-3328 is capable of being labelled with 18F for positron emission tomography (PET) imaging.
    MK-3328
  • HY-124481
    Oleocanthal
    		Inhibitor ≥99.0%
    Oleocanthal is an orally active phenolic seciridoid compound. Oleocanthal can be extracted from olive oil. Oleocanthal inhibits COX-1 and COX-2, reduces ROS and NO, and upregulates Nrf-2 and HO-1. Oleocanthal reduces Aβ deposition. Oleocanthal exhibits anti-Leishmania activity against promastigotes and amastigotes of L. major, with IC50 values of 18.7 and 87 μg/mL, respectively. Oleocanthal exhibits anticancer activity against colon, breast, liver, and melanoma cancers. Oleocanthal also exhibits anti-inflammatory and neuroprotective properties. Oleocanthal can be used in Alzheimer's disease research.
    Oleocanthal
  • HY-P1474A
    β-Amyloid (22-35) (TFA)
    β-Amyloid 22-35 (Amyloid β-Protein 22-35) TFA, the residues 22-35 fragment ofβ-amyloid protein, has a cytotoxic effect on cultured neurons from the rat hippocampus in serum-free medium. β-Amyloid 22-35 TFA forms aggregates and typical amyloid fibrils resembling those of the β-amyloid protein in neutral buffer solution).
    β-Amyloid (22-35) (TFA)
  • HY-156842
    MCAAD-3
    MCAAD-3 is a near-infrared Aβ imaging probe with blood-brain barrier penetrability. MCAAD-3 has a strong affinity for Aβ polymers (Ki >106 nM) and can label Aβ plaques in the brains of transgenic mice.
    MCAAD-3
  • HY-P1362A
    β-Amyloid (42-1), human TFA
    β-Amyloid (42-1), human TFA is the inactive form of Amyloid β Peptide (1-42). β-Amyloid (42-1), human TFA is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease.
    β-Amyloid (42-1), human TFA
  • HY-153417
    Anti-amyloid agent-1
    		Inhibitor 99.03%
    Anti-amyloid agent-1 is a potent anti-amyloid compound and inhibits amyloid aggregation. Anti-amyloid agent-1, compound ex1140 from patent WO2012119035A1, provides a useful method for amyloidosis treatment research.
    Anti-amyloid agent-1
  • HY-P5096
    FITC-β-Ala-Amyloid β-Protein (1-42)
    FITC-β-Ala-Amyloid β-Protein (1-42) is a FITC tagged Aβ1-42 peptide. Aβ1-42 plays a key role in the pathogenesis of Alzheimer’s disease.
    FITC-β-Ala-Amyloid β-Protein (1-42)
  • HY-N6640
    2-O-Acetyl-20-hydroxyecdysone
    		99.61%
    2-O-Acetyl-20-hydroxyecdysone, an ecdysterones in insects and terrestrial plants, inhibits amyloid-β42 (Aβ42)-induced cytotoxicity. 2-O-Acetyl-20-hydroxyecdysone could decrease Aβ oligomer formation through promotion of fibrogenesis, transforming Aβ oligomers to the low-toxicity fibrils.
    2-O-Acetyl-20-hydroxyecdysone
  • HY-111513
    4-(6-Bromo-2-benzothiazolyl)-N-methylbenzenamine
    		Inhibitor 98.60%
    4-(6-Bromo-2-benzothiazolyl)-N-methylbenzenamine is a potent amyloid imaging agent which binds to Amyloid-β (1-40) with a KD of 1.7 nM.
    4-(6-Bromo-2-benzothiazolyl)-N-methylbenzenamine
  • HY-145343A
    (9R)-RO7185876
    		Inhibitor 99.46%
    (9R)-RO7185876 (Compound example 16) is a γ-secretase inhibitor. (9R)-RO7185876 inhibits Αβ42 secretion. (9R)-RO7185876 can be used for the researches of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, multi-infarct dementia, dementia pugilistica or Down syndrome.
    (9R)-RO7185876
  • HY-P1850A
    β-Amyloid (1-20) (acetate)
    β-Amyloid (1-20) acetate is the acetate form of β-Amyloid (1-20)，which consists of amino acids 1 to 20 of beta amyloid protein.
    β-Amyloid (1-20) (acetate)
  • HY-19771
    amyloid P-IN-1
    		Inhibitor 99.59%
    amyloid P-IN-1 is used in the research of diseases or disorders wherein depletion of serum amyloid P component (SAP), including amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.
    amyloid P-IN-1
  • HY-W117986
    Aβ aggregation-IN-1
    		Inhibitor 99.92%
    Aβ aggregation-IN-1 (Compound 1b) is an amyloid-beta precursor protein inhibitor. Aβ aggregation-IN-1 inhibits amyloid-beta aggregation and disaggregation of fibrillogenesis with IC50 values of 3.92 and 7.19 M, respectively. Aβ aggregation-IN-1 also inhibits malondialdehyde formation, augments the intracellular reduced glutathione (GSH) levals and inhibits caspase 3 in neuronal cells.
    Aβ aggregation-IN-1
  • HY-B0320AR
    Cromolyn disodium (Standard)
    		Inhibitor
    Cromolyn disodium (Standard) (Cromoglycate disodium (Standard)) is the analytical standard of Cromolyn disodium (HY-B0320A). This product is intended for research and analytical applications. Cromolyn (Cromoglycate) disodium is an orally active GSK-3β inhibitor with an IC50 of 2.0 μM. Cromolyn disodium is also a mast cell stabilizer that can inhibit the release of mediators from mast cells, regulate reflex bronchoconstriction, and reduce non-specific bronchial hyperreactivity, and Cromolyn disodium can be used in the research of bronchial asthma. In addition, Cromolyn disodium has multiple activities such as anti-inflammatory, anti-allergic, anti-histamine, anti-cancer, and neuroprotective effects.
    Cromolyn disodium (Standard)
  • HY-P1522
    β-Amyloid (29-40)
    β-Amyloid (29-40) is a fragment of Amyloid-β peptide.
    β-Amyloid (29-40)
  • HY-116753
    (-)Clausenamide
    		Inhibitor 99.92%
    (-)Clausenamide is an active alkaloid isolated from the leaves of Clausena lansium (Lour.) Skeels, and improves cognitive function in both normal physiological and pathological conditions. (-)Clausenamide inhibits β-amyloid (Aβ) toxicity, blocking neurofibrillary tangle formation by inhibiting the phosphorylation of tau protein. (-)Clausenamide exerts a significant neuroprotective activity against Aβ25-35. (-)Clausenamide can be used for researching Alzheimer's disease (AD).
    (-)Clausenamide
Cat. No. Product Name / Synonyms Application Reactivity